Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug 30:11:2517-2526.
doi: 10.2147/DDDT.S135785. eCollection 2017.

Secondary prevention of major cerebrovascular events with seven different statins: a multi-treatment meta-analysis

Ping Zhong #  1   2 , Danhong Wu #  3 , Xiaofei Ye  4 , Ying Wu  2 , Tuming Li  2 , Shuwen Tong  2 , Xueyuan Liu  1   5
Affiliations
Review

Secondary prevention of major cerebrovascular events with seven different statins: a multi-treatment meta-analysis

Ping Zhong et al. Drug Des Devel Ther. .

Abstract

Background: Statins have been recommended for the use in atherosclerotic cardiovascular diseases, but different statins have distinct pharmacological characteristics. This multi-treatment meta-analysis aimed to evaluate the efficacy of seven statins in the secondary prevention of major cerebrovascular events (CVEs).

Methods and analyses: The PubMed, Embase, Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials were searched to identify studies published between January 1, 2011, and June 30, 2016. The included randomized controlled trials investigated the efficacy of lovastatin, atorvastatin, fluvastatin, simvastatin, pitavastatin, pravastatin or rosuvastatin in the secondary prevention of CVEs. The primary outcomes were CVEs; the secondary outcomes were all-cause death, fatal stroke and nonfatal stroke. Meta-analysis and network meta-analysis were used for data synthesis.

Results: A total of 42 studies with 82,601 patients were included for analysis. In the secondary prevention of cardiovascular diseases, the major CVEs in pravastatin (risk ratio [RR] 0.87, 0.76-0.99)- and atorvastatin (RR 0.59, 0.49-0.72)-treated patients reduced significantly compared with controls. Indirect comparisons with network meta-analysis showed that RR was 0.60 (0.40-0.92) for atorvastatin compared with rosuvastatin. Compared to controls, the all-cause death was reduced by 12% in statins-treated patients (RR 0.88, 0.81-0.96). Indirect comparisons with network analysis showed a significant difference in the nonfatal stroke between fluvastatin-treated patients and lovastatin-treated patients (RR 0.28, 0.07-0.95).

Conclusion: Different statins have distinct pharmacological characteristics, and there are differences in statistical and clinical outcomes among several statins.

Keywords: atherosclerotic cardiovascular disease; cerebrovascular event; controlled trial; primary outcome; randomized.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Flowchart of study inclusion.
Figure 2
Figure 2
Meta-analysis of seven statins in the prevention of major CVEs. Notes: Rosuvastatin vs atorvastatin: K=2, n=3,561, I2=0%; RR =0.68 (0.15–3.13); atorvastatin vs simvastatin: K=1, n=1,093, I2=0%; RR = not estimated; rosuvastatin vs control: K=2, n=9,585, I2=61%; RR =1.04 (0.75–1.44); atorvastatin vs pravastatin: K=3, n=5,341, I2=0%; RR =1.20 (0.71–2.00) and atorvastatin vs control: K=7, n=12,768, I2=7%; RR =0.59 (0.49–0.72). Abbreviations: CVE, cerebrovascular event; RR, risk ratio.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–2236. - PubMed
    1. Finkel JB, Duffy D. 2013 ACC/AHA cholesterol treatment guideline: paradigm shifts in managing atherosclerotic cardiovascular disease risk. Trends Cardiovasc Med. 2015;25(4):340–347. - PubMed
    1. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8(5):453–463. - PubMed
    1. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee, editor. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25(5):457–507. - PubMed
    1. Chinese Society of Neurology, Neurology Cerebrovascular Group 2014 Guideline of the secondary prevention of ischemic stroke and transient ischemic attack in China. Chin J Neurol. 2015;48(4):258–273.

MeSH terms

Substances